ExodusPoint Capital Management’s Pliant Therapeutics PLRX Stock Holding History

ExodusPoint Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-93,804	Closed	-$1.24M	–	1887
2024 Q4	$1.24M	Sell	93,804 -11,672	-11%	-$159K	0.01%	880
2024 Q3	$1.18M	Buy	105,476 +12,232	+13%	+$153K	0.01%	924
2024 Q2	$1M	Buy	93,244 +15,668	+20%	+$202K	0.01%	1020
2024 Q1	$1.16M	Buy	77,576 +59,471	+328%	+$981K	0.01%	895
2023 Q4	$328K	Sell	18,105 -9,017	-33%	-$137K	﹤0.01%	1156
2023 Q3	$470K	Buy	27,122 +6,902	+34%	+$120K	﹤0.01%	1266
2023 Q2	$366K	Buy	20,220 +5,242	+35%	+$124K	﹤0.01%	1467
2023 Q1	$398K	Sell	14,978 -26,247	-64%	-$747K	﹤0.01%	1398
2022 Q4	$797K	Buy	+41,225	New	+$862K	0.01%	1021
2021 Q3	–	Sell	-14,499	Closed	-$422K	–	2515
2021 Q2	$422K	Buy	+14,499	New	+$451K	﹤0.01%	1545

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

ExodusPoint Capital Management's PLRX Position: Q1 2025 in Review

ExodusPoint Capital Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 93,804 shares — an estimated $1.24M sold.

ExodusPoint Capital Management first reported a position in PLRX in Q2 2021 and held it in 10 quarters. The position peaked at $1.24M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

ExodusPoint Capital Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 93,804 Pliant Therapeutics shares in Q1 2025, an estimated $1.24M.
ExodusPoint Capital Management first reported a position in Pliant Therapeutics in Q2 2021 and held it in 10 quarters.
ExodusPoint Capital Management's Pliant Therapeutics position peaked at $1.24M in Q4 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.